Anavex

AVXL

ATLANTA, GA – – (Globe Newswire – January 3, 2024) – – Holzer & Holzer, LLC is investigating whether Anavex Life Sciences Corp.  (“Anavex” or the “Company”) (NASDAQ: AVXL) complied with federal securities laws.  On January 2, 2024, Anavex announced topline results from the phase 2/3 clinical trial, EXCELLENCE, and disclosed that the study failed to meet a “co-primary endpoint, the Clinical Global Impression – Improvement scale (CGI-I).” Following this news, the price of the Company’s stock dropped.

If you purchased Anavex stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/anavex/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share